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Abstract
Background: Promiscuous T-cell epitopes that can be presented by multiple human leukocyte antigens (HLAs) are
prime targets for vaccine and immunotherapy development because they are effective in a high proportion of the
human population. Although there are a number of epitope databases currently available online, the epitope data
in these databases were annotated using specific MHC restrictions, and none of these databases was specifically
designed for retrieving data on promiscuous epitopes.
Description: HLAsupE is an integrated database of HLA supertype-specific epitopes (promiscuous T-cell epitopes in
the context of HLA supertypes). The source data for the T-cell activities and HLA-binding capacities of peptides with
a specific HLA restriction were extracted from public epitope databases. After a manual curation, these
allele-specific data were integrated into supertype-specific datasets based on the defined supertypes and
corresponding alleles. Each supertype-specific peptide in HLAsupE is annotated in terms of its cross-reactivity to
HLA molecules within the same supertype. Promiscuous peptides that can be presented by multiple HLA molecules
across multiple HLA supertypes were also included in this database. Several web-based tools are provided to access
and download the data.
Conclusions: HLAsupE is the first database of promiscuous T cell epitopes that is organized based on the HLA
supertypes. The main advantage of this database is the ability to search for promiscuous T-cell epitopes based on
the cross-reactivity to specific alleles or supertypes. HLAsupE will be a valuable resource for the development of
epitope-based vaccines and immunotherapies with broad coverage of human population.
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Background
In the vertebrate immune system, short peptides derived
from endogenous or exogenous antigens are presented by
major histocompatibility complex (MHC) molecules on the
surface of antigen presenting cells for recognition by T-cell
receptors (TCRs). MHC-presented peptides that can trigger
cell-mediated immune responses are termed T-cell epitopes
and play a vital role in the development of epitope-based
vaccines and immunotherapies against viral infections,
tumors and autoimmune diseases [1–4]. However, human
MHC (human leukocyte antigens, HLAs) genes exhibit a
high level of polymorphism, and their distribution in the
human population varies with ethnicity and region. There-
fore, population coverage is a key question that should be
considered during the development of epitope-based vac-
cines. Promiscuous T-cell epitopes that can be presented by
multiple MHC molecules have great potential in the devel-
opment of vaccines with wide population coverage, as fewer
epitopes would be needed to cover a larger portion of spe-
cific populations [5, 6].
At present, a number of epitope databases, such as SYF-
PEITHI [7], MHCBN [8], AntiJen [9], and IEDB [10], have
been constructed and reported. However, the data in these
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databases are annotated using specific MHC restrictions,
and none of these databases was specifically designed for
retrieving data on promiscuous epitopes. As a result, the
retrieval of such data from these databases is indirect and
often requires users to possess previous experience with
sequence analysis. A more specific database would be of
great interest for immunologists and vaccinologists who
aim to develop novel vaccines with broad coverage of the
human population.
Although more than 10,000 HLA alleles have been
identified to date [11], most HLA molecules can be
clustered into supertypes based on their overlapping
peptide-binding specificities or the residue compos-
ition at their peptide-binding sites [12–15]. Peptides
that bind to an HLA molecule with high affinity can
also bind to multiple molecules within the same
supertype [16]. These promiscuous epitopes in the
context of HLA supertypes are defined as HLA
supertype-specific epitopes. HLAsupE is an integrated
database of HLA supertype-specific epitopes. The
source data for the T-cell activities and HLA-binding
capacities of peptides with a specific HLA restriction
were extracted from public epitope databases. After a
manual curation, these allele-specific data were inte-
grated into supertype-specific datasets based on the
defined supertypes and corresponding alleles. Each of
the supertype-specific peptides in HLAsupE was anno-
tated in terms of its cross-reactivity to HLA molecules
within the same supertype. Promiscuous peptides that
can be presented by multiple HLA molecules across
multiple HLA supertypes were also included in this
database. HLAsupE is the first database of promiscu-
ous T cell epitopes that is organized based on the HLA
supertypes. HLAsupE will be a valuable resource for
the development of epitope-based vaccines and im-
munotherapies with broad coverage of human
population.
Construction and content
HLAsupE is a web-based server that combines a MySQL
database management system and Perl programs with a
dynamic web interface based on PHP.
Data source and curation
Data on the T cell activity and HLA-binding capacity of
peptides were mainly extracted from SYFPEITHI [7]
and IEDB [10]. The overlapping peptide data extracted
from different databases were first removed according
to the PMID number. The T cell activities of peptides
with specific HLA restrictions were classified into two
groups, Positive (P) or Negative (N), based on the an-
notation in the source databases. The activity of a spe-
cific HLA-restricted peptide with multiple experimental
results was defined using the relative number of
positive and negative reports. The peptide was defined
as "contradictory" (C) if the number of positive reports
equaled the number of negative reports. The HLA-
peptide binding capacity was determined by the quanti-
tative binding affinity (IC50 or EC50). According to the
conventional standard, peptides with a binding affinity
stronger than 500 nM (IC50 < 500 nM) were classified
as binders (Positive), and peptides with a weaker bind-
ing affinity (IC50 ≥ 500 nM) were defined as non-
binders (Negative). Peptides without quantified binding
affinities were classified based on their annotations in
the source databases. The generated datasets, in which
each specific HLA restricted peptide has a unique rec-
ord, were used to define supertype-specific data.
Generation of HLA supertype-specific datasets
Most of the known HLA class I and class II molecules can
be clustered into supertypes. The HLA class I supertypes
for the HLA-A and B loci used here were defined by Sidney
et al [15], and the supertypes used for the HLA-C loci were
based on the classification presented by Doytchinova [12].
The HLA class II supertypes used were consistent with
Doytchinova’s definition [13]. Due to the relatively low
number of HLA-DPA and DPB alleles with available pep-
tide data, all available HLA-DPA and DPB alleles in this
database were classified into one DP supertype. The super-
types and alleles with available peptide data can be found
on the webpage of HLAsupE (http://www.immunoinforma-
tics.net/HLAsupE/downloads/alleles.xlsx). The curated T
cell activities and HLA-binding capacities of the peptide
data were integrated into supertype-specific datasets based
on HLA restriction and supertype. Each peptide in the
supertype-specific datasets was annotated in terms of its
cross-reactivity to HLA molecules within one supertype.
Architecture of HLAsupE
HLAsupE consists of six interrelated data blocks: (1) HLA
supertype-specific epitope data: the restriction of promiscu-
ous epitopes to HLA molecules within one supertype and
basic information on the epitopes (e.g., sequence, source
protein and organism); (2) HLA supertype-specific binding
peptide data: the cross-binding abilities of peptides to HLA
molecules within one supertype and basic information on
the peptides; (3) HLA-peptide binding data: detailed informa-
tion concerning the binding ability of a given peptide to a
certain HLA molecule; and (4) T-cell activity data: the T-cell
activity of a given HLA restricted peptide. The quantitative
HLA-peptide binding data and the detailed T-cell activity
data available in HLAsupE were mainly extracted from
IEDB, and hyperlinks to the source data are provided. The
Source Protein (5) and Reference data (6) are also imbedded
in this database, and hyperlinks to GenBank and PubMed
are provided. An overview of the database and the contents
of the data blocks are schematically represented in Fig. 1.
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Statistics of HLAsupE
The latest version of the database maintains 17,889
unique records of HLA supertype-specific epitopes (SupEs)
and 107,747 records of HLA supertype-specific binding
peptides (SupBs). Non-redundant datasets on the detailed
T-cell activity and HLA-binding capacity of specific HLA
restricted peptides contain 31,793 and 196,510 records, re-
spectively. Statistics based on HLA supertypes are shown in
Table 1. The numbers of alleles with available peptide data
in the SupE and SupB datasets are 195 and 204, respect-
ively. The Source Protein dataset contains more than 14,000
proteins from approximately 1400 different source species
and strains. The peptide datasets contained in HLAsupE




To facilitate the use of HLAsupE, we provide several online
tools allowing users to search for and analyze HLA
supertype-specific peptides. The following options are pro-
vided: (1) retrieving and browsing supertype-specific pep-
tides by peptide sequence, supertype, cross-reactivity to
specific alleles and source species; (2) mapping supertype-
specific peptides onto a specific protein sequence; and (3)
searching for mutant analogues of a specific peptide. These
servers are easy to use, and a tutorial is also provided on
the tutorial page: (http://www.immunoinformatics.net/
HLAsupE/tutorial.htm).
We can use a query of HLA supertype-specific epitopes
as an example to demonstrate the usage of HLAsupE. If a
user chooses a specific source species, e.g., “Hepatitis B
virus”, the statistics of epitopes related to HBV will be
shown based on supertypes in tabular format (Fig. 2a). “De-
tailed Data” will give the curated T-cell activities of peptides
presented by alleles of the same supertype in a similar for-
mat as in Fig. 2b. Figure 2b lists the peptides (sectional) that
could be presented by HLA-A*02:01 and HLA-A*02:03 that
share positive T cell activity for the restrictions of both al-
leles. The source protein and species of each peptide are
also given in the results. The T-cell activities of each peptide
listed in Fig. 2b are provided through a hyperlink and pre-
sented in the format depicted in Fig. 2c, which displays an
overview of the cross-reactivity of the selected peptide to
alleles of the same supertype followed by the experimental
results obtained using different assay types or by different
labs. The detailed data for each record listed in Fig. 2c are
presented as shown in Fig. 2d. If a user is interested in the
HLA-binding abilities of the selected peptide, the cross-
binding abilities of the peptide to alleles can be obtained by
clicking “Click here to find the HLA-binding data of the
peptide” and are shown in the format presented in Fig. 2e,
which presents an overview of the cross-binding ability to
alleles of the same HLA supertype and the experimental re-
sults obtained using different assay types or by different
labs. The query method for HLA supertype-specific binding
peptides is the same as that for supertype-specific epitopes.
Promiscuous peptides in the context of different
supertypes
In addition to HLA supertype-specific peptides, HLA-
supE contains a large number of promiscuous peptides
that can be presented by multiple HLA molecules within
different supertypes (Epitopes: 630, Binders: 5,166). The
collection of these promiscuous T-cell epitopes provides
additional evidence for understanding HLA function and
Fig. 1 Architecture of HLAsupE
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the development of epitope-based vaccines. The statis-
tics on promiscuous peptides across every two super-
types are listed in Table 2. Promiscuous binding mainly
occurs between supertypes of the same HLA class (class
I or II), but some peptides can be presented by multiple
alleles across HLA classes. To facilitate the use of these
promiscuous peptides, we also developed query tools for
promiscuous T-cell epitopes and for promiscuous bind-
ing peptides (http://www.immunoinformatics.net/HLA-
supE/cross.html). These data can be output based on the
source species or/and the supertype selected by the user.
Discussion
HLAsupE is a database of promiscuous T cell epitopes
that is organized based on HLA supertypes. Although
promiscuous binding has been considered a hallmark of
HLA class II restricted peptides [17–19] and the promiscu-
ous recognition of CTL epitopes in the context of unrelated
HLA class I molecules has been reported and investigated
[20], supertype-based cross-binding remains predominant
in promiscuous data. Moreover, the supertypes of HLA
molecules have been well defined [12, 13, 15], which make
it possible to integrate the promiscuous peptides or epi-
topes based on HLA supertypes.
The data in HLAsupE were extracted from SYF-
PEITHI [7] and IEDB [10]. The widely known database
SYFPEITHI [7] contains only positive data and lacks
quantitative descriptions of these peptide data and nega-
tive reactive peptides. The quantitative HLA-peptide
binding data and the detailed T-cell activity data avail-
able in HLAsupE were mainly extracted from IEDB.
IEDB is the largest database of immune epitopes and
covers almost all peptide data in the other known epi-
tope databases. The experimental data on the T-cell
activity and MHC-binding capacity of peptides included
in IEDB have been detected using various assay methods
or submitted by different laboratories. Therefore, the re-
dundancy of data for specific MHC-restricted peptides is
inevitable. In HLAsupE, the T-cell activity and MHC-
binding capacity of each HLA-restricted peptide were
curated based on the available experimental data, and
supertype-specific data were generated using these cu-
rated data such that each HLA-restricted peptide has a
unique record. Thus, the data included in the Supertype
Epitope and Supertype-binding data blocks (Fig. 1) are
non-redundant. To maintain the integrity of the data,
the T-cell activity and HLA-peptide binding data blocks
contain all the data extracted from the source databases,
which are highly redundant because of the overlap of
peptide data in different databases and the inherent re-
dundancy of the data in the source database. In HLA-
supE, a hyperlink to the publication or source database
is provided for each record of the detailed information
of specific-allele-restricted peptides to ensure data trace-
ability, which should help the user to further inspect a
specific epitope, particularly when encountering records
with contradictory results.
As a database of promiscuous epitopes, the main advan-
tage of HLAsupE with respect to the existing databases of
T-cell epitopes is that each epitope in HLAsupE was an-
notated with its cross-reactivity to HLA molecules within
one supertype (HLA supertype-specific data blocks). As a
result, users can instantly retrieve the promiscuous epi-
topes with multiple selected HLA restrictions. The query
tools in HLAsupE now allow users to define the promis-
cuous binding ability using five different HLA molecules
within one supertype. Moreover, HLAsupE can also be
used for the query of promiscuous peptides with different
binding affinities to multiple HLA molecules, e.g., peptides
Table 1 Statistical analysis of data included in HLAsupE
Label Supertype SupE SupB T-cell activity HLA-binding
P N C P N
A A1 1136 6839 108 2518 9 2817 10175
B A2 4124 15625 1615 2465 182 13623 19297
C A3 1904 9397 259 7519 108 9190 15557
D A24 1599 4341 230 2526 16 1714 4280
E B7 1224 6229 470 1730 79 3232 7488
F B8 35 3434 31 4 – 1489 2402
G B27 119 3952 106 30 2 1333 5492
H B44 1256 8354 148 4254 5 6368 6642
I B58 95 5151 98 4 2 2414 5466
J B62 165 5224 80 82 3 2362 4385
K C1 18 619 21 – – 580 63
L C4 48 1299 45 3 – 560 791
M A01A03 8 2164 6 1 1 586 1578
N A01A24 664 2145 27 636 1 858 1287
O DP 173 1225 112 74 2 1115 3984
P DQ1 337 1752 174 164 14 1005 2239
Q DQ2 139 1630 140 34 2 507 1343
R DQ3 332 1760 187 247 9 1113 2840
S DQA – 90 – – – – 360
T DR1 1604 10262 1373 510 33 8713 7902
U DR3 620 3741 421 232 14 1577 5120
V DR4 1353 5082 1104 446 29 4751 6827
W DR5 549 4545 531 121 2 3970 6359
X DR9 387 2887 335 57 2 2075 2681
SUM 17889 107747 7621 23657 515 71952 124558
31793 196510
SupE and SupB: the statistics of unique records restored in the HLA
supertype-specific epitope data block and the HLA supertype-specific binding
peptide data block. The statistics on T-cell activity and HLA-binding capacity,
which represent the number of HLA-peptide complexes with experimentally
verified activity, were derived from non-redundant records. P, N and C
represent positive, negative and contradictory records, respectively
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that can bind to HLA-A*0201and A*0202 but not A*0203
[A*0201(+), A*0202(+), A*0203(-)], which would be useful
for the analysis of allele-specific recognition patterns. In
addition to HLA supertype-specific peptides, HLAsupE
also has a collection of a large number of promiscuous
peptides that can be presented by multiple HLA mole-
cules within different supertypes and provide correspond-
ing query tools for these promiscuous data.
There are large amounts of data on peptides presented
by serological HLA molecules (such as HLA-A2, B51 B7
and DR1) included in SYFPEITHI and IEDB. However,
the HLA supertypes in HLAsupE were defined based on
the published data [12, 13, 15], and the HLA molecules
encoded by HLA alleles (genotype) were used in the
identification of the HLA supertypes. Therefore, the
peptides presented by serological proteins were difficult
to integrate into the supertype-specific dataset with an
exact allele restriction. These data were only maintained
in the T-cell activity and HLA-peptide binding data
blocks; as a result, these peptide data can be displayed
when a user inspects the detailed activity of a specific
peptide, but a direct query of these peptides is currently
unavailable in HLAsupE.
The MHC restriction and population coverage are key
questions in the development of epitope-based vaccines
that contain at least two antigenic epitopes: a Th-epitope
and an epitope that will either induce specific B-cell or
CTL responses [4]. Promiscuous T-cell epitopes have
Fig. 2 Screenshots of HLAsupE. a HLA supertype-specific epitopes browsed by source species (Hepatitis B virus); b HLA supertype-specific epitopes
with two restrictions (HLA-A*0201(P), A*0203(P)); c Overview of the cross-reactivity of peptide “FLPSDFFPSV” to alleles of the same supertype followed
by the experimental results obtained using different assay types or by different labs; d Detailed information of the first record in C; e Overview of the
cross-binding ability of peptide “FLPSDFFPSV” to alleles of the same supertype and the experimental results obtained using different assay types or by
different labs
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great potential in the development of vaccines with wide
population coverage. However, the distribution of HLA
genes in the human population varies with ethnicity and
region. The frequency of alleles in a specific population
should be taken into account. At present, Allele Frequency
Net Database (AFND) [21] and Population Coverage tool
[22] have been built to address this issue. By combining
with these tools, our database should be more useful in
practice.
We will continue to update our database by extracting
and curating HLA-restricted peptide data from all avail-
able epitope databases and published literatures. To make
HLAsupE an even more powerful resource, we will further
improve the functionality and architecture of HLAsupE to
facilitate the use and analysis of promiscuous peptides.
Conclusions
HLAsupE is the first database of promiscuous T cell epi-
topes and was constructed by integrating allele-specific
data into supertype-specific data. The main advantage of
this database server is the ability to search for promiscu-
ous epitopes or binding peptides based on cross-reactivity
to specific alleles or supertypes. This database is a valuable
resource for the development of epitope-based vaccines
with broad coverage of the human population and to
obtaining a further understanding of the cellular immune
response.
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Availability of data and materials
HLAsupE is now freely available at http://www.immunoinformatics.net/
HLAsupE/. The data were maintained using the database management
Table 2 Statistical analysis of promiscuous peptides across every two supertypes
A B C D E F G H I J K L M N O P Q R T U V W X
A – 193 152 81 131 28 98 22 207 295 32 24 319 61
B 9 – 119 68 114 71 100 45 115 156 31 23 29 37 1 1
C 3 4 – 20 62 7 57 16 96 112 34 16 47 112 5 4 4 2 4
D 5 16 3 – 44 8 10 12 48 58 8 6 101 7
E 3 15 3 11 – 71 58 20 134 227 21 8 14 16
F 3 1 – 65 6 19 79 7 6 25 1 1 1 1
G 3 1 – 44 34 157 35 20 4 46
H 1 2 1 1 – 26 33 3 10 9 1
I 1 1 2 2 – 192 20 8 25 27
J 1 2 3 3 – 32 8 44 44 1 1
K 3 2 2 – 20 9 1
L 4 5 1 1 – 2 5
M 10 1 2 – 4
N 2 1 3 1 1 –
O 1 2 – 192 99 200 310 168 270 285 265
P 2 – 104 336 341 177 292 320 292
Q 1 3 – 138 127 92 134 108 100
R 1 1 43 4 – 476 234 402 403 380
T 19 2 10 5 1 9 17 26 – 782 1714 1550 1310
U 9 4 1 6 7 1 9 53 – 746 724 583
V 10 1 9 3 5 18 1 12 171 51 – 1361 1088
W 6 1 1 7 8 13 93 38 71 – 1089
X 2 2 5 10 1 87 7 32 34 –
Promiscuous peptides that can be presented by multiple HLA molecules within different supertypes were collected, and a statistical analysis of these promiscuous
data across every two supertypes was performed. Statistics on promiscuous epitopes are shown in the lower triangle, and statistics on promiscuous binding
peptides are shown in the upper triangle. The values in the table indicate the numbers of peptides that can be presented by HLA molecules within the two
supertypes indicated in the row and column headers. The supertype names are presented in capital letters according to the labels in Table 1
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system MySQL (http://www.mysql.com/). The web interface was constructed
on PHP (http://www.php.net/), Perl (http://www.perl.org/) and JavaScript
(http://www.javascriptsource.com/).
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